Insider Trading Activity MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) – CEO Sold 110,093 shares of Stock

ME Staff
-
0

Insider Trading Activity For MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX)

John David Hansen , CEO of MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) reportedly Sold 110,093 shares of the company’s stock at an average price of 0.96 for a total transaction amount of $105,689.28 SEC Form

Insider Trading History For MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX)

  • On 9/12/2014 Jim J Antonopoulos, Director, sold 11,892 with an average share price of $6.00 per share and the total transaction amounting to $71,352.00.
  • On 12/16/2014 Robert Hoffman, Director, bought 10,000 with an average share price of $2.40 per share and the total transaction amounting to $24,000.00.
  • On 12/16/2014 Gregory P Hanson, CFO, bought 3,000 with an average share price of $2.50 per share and the total transaction amounting to $7,500.00.
  • On 12/17/2014 Kenneth M Cohen, Director, bought 2,500 with an average share price of $1.80 per share and the total transaction amounting to $4,500.00.
  • On 5/22/2015 Kenneth M Cohen, Director, bought 3,500 with an average share price of $2.30 per share and the total transaction amounting to $8,050.00.
  • On 5/29/2015 Paul V Maier, Director, bought 5,000 with an average share price of $2.30 per share and the total transaction amounting to $11,500.00.
  • On 3/24/2016 Jeffrey V. Ravetch, Director, sold 131,500 with an average share price of $0.60 per share and the total transaction amounting to $78,900.00.

    • Analyst Ratings History For MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX)

    • On 4/13/2016 Laidlaw Initiated Coverage of rating Buy with a price target of $2.50

    Recent Trading Activity for MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX)
    Shares of MabVax Therapeutics Holdings, Inc. closed the previous trading session at 0.90 down -0.08 8.53% with shares trading hands.